Zoetis Inc. (NYSE:ZTS) Shares Acquired by Nwam LLC

Nwam LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 19.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,032 shares of the company’s stock after buying an additional 664 shares during the period. Nwam LLC’s holdings in Zoetis were worth $702,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Evermay Wealth Management LLC raised its holdings in shares of Zoetis by 439.3% in the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after buying an additional 112 shares during the last quarter. Worth Asset Management LLC bought a new position in shares of Zoetis in the first quarter valued at $26,000. Pacifica Partners Inc. lifted its position in shares of Zoetis by 76.9% during the 2nd quarter. Pacifica Partners Inc. now owns 161 shares of the company’s stock valued at $27,000 after acquiring an additional 70 shares during the last quarter. Finally, Altshuler Shaham Ltd acquired a new position in shares of Zoetis in the 2nd quarter worth $29,000. Institutional investors and hedge funds own 89.47% of the company’s stock.

Zoetis Trading Down 1.1 %

Shares of NYSE ZTS opened at $190.89 on Thursday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.16 and a current ratio of 3.87. The stock has a market cap of $87.64 billion, a price-to-earnings ratio of 38.80, a PEG ratio of 2.81 and a beta of 0.85. Zoetis Inc. has a 52 week low of $151.03 and a 52 week high of $201.92. The business has a 50 day simple moving average of $187.58 and a 200 day simple moving average of $180.94.

Zoetis (NYSE:ZTSGet Free Report) last released its quarterly earnings data on Thursday, November 2nd. The company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.01. The business had revenue of $2.15 billion during the quarter, compared to analyst estimates of $2.17 billion. Zoetis had a net margin of 27.24% and a return on equity of 52.22%. On average, research analysts predict that Zoetis Inc. will post 5.41 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, January 19th will be issued a dividend of $0.432 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.91%. Zoetis’s dividend payout ratio is currently 30.49%.

Insider Activity at Zoetis

In other Zoetis news, CEO Kristin C. Peck sold 13,000 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $176.84, for a total transaction of $2,298,920.00. Following the transaction, the chief executive officer now owns 56,843 shares in the company, valued at $10,052,116.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Zoetis news, CEO Kristin C. Peck sold 13,000 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $176.84, for a total transaction of $2,298,920.00. Following the completion of the sale, the chief executive officer now directly owns 56,843 shares in the company, valued at $10,052,116.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 2,500 shares of Zoetis stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $200.00, for a total value of $500,000.00. Following the completion of the transaction, the executive vice president now owns 19,415 shares in the company, valued at $3,883,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,423 shares of company stock valued at $2,962,716. Corporate insiders own 0.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 11th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, November 6th. The Goldman Sachs Group boosted their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday. Stifel Nicolaus raised their price objective on shares of Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a research note on Friday, January 12th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $230.00 target price on shares of Zoetis in a report on Tuesday, December 19th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus target price of $223.78.

View Our Latest Analysis on ZTS

Zoetis Company Profile

(Free Report)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.